Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leukemic risk in thrombocythemia].

E Liozon1, P Turlure

  • 1Service de Médecine Interne A, CHRU Dupytren, 2, rue Martin-Luther-King, 87042 Limoges.

Annales De Medecine Interne
|August 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of the chewing gum test for the diagnosis of giant cell arteritis: a multicentre pilot study.

Scandinavian journal of rheumatology·2026
Same author

Recurrent (or episodic) fever of unknown origin (FUO) as a variant subgroup of classical FUO: A French multicentre retrospective study of 170 patients.

Clinical medicine (London, England)·2024
Same author

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Thrombosis research·2024
Same author

Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.

Leukemia research·2023
Same author

Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.

The British journal of dermatology·2021
Same author

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021
Same journal

[Consensus Development Conference on Thrombosis and Pregnancy. 14 March 2003, Paris, France. Proceedings].

Annales de medecine interne·2004
Same journal

Kartagener's syndrome and renal failure.

Annales de medecine interne·2004
Same journal

Inflammatory pseudotumor of lymph nodes.

Annales de medecine interne·2004
Same journal

[Necrolytic migratory erythema revealing glucagonoma without diabetes].

Annales de medecine interne·2004
Same journal

[Bilateral primary non-Hodgkin's lymphomas of the adrenals].

Annales de medecine interne·2004
Same journal

[Acute "pseudo-angiocholitis" due to colonic adenocarcinoma in a man with primary sclerosis cholangitis and ulcerative colitis].

Annales de medecine interne·2004
See all related articles

Leukemic transformation (LT) in essential thrombocytemia (ET) is a serious complication, often unpredictable, with a poor prognosis. The leukemogenic risk of myelosuppressive drugs in ET requires further investigation through large-scale studies.

Area of Science:

  • Hematology
  • Oncology
  • Clonal Hematopoiesis

Context:

  • Essential Thrombocythemia (ET) is a myeloproliferative neoplasm.
  • Leukemic transformation (LT) is a feared complication of ET.
  • The role of prior treatments in LT is debated.

Purpose:

  • To define the pathogenesis, incidence, clinical presentation, and prognosis of LT in ET patients.
  • To compare LT incidence in treated versus untreated ET patients.
  • To identify risk factors for LT, including myelosuppressive drug risks.

Summary:

  • LT in ET is poorly documented, with incidence varying by study type.
  • Cytogenetic abnormalities are more complex at blastic crisis.
  • LT has a poor prognosis, with median survival around 6 months.

Related Experiment Videos

  • Myelodysplastic syndrome preceding LT indicates a poor outcome.
  • The leukemogenic risk of myelosuppressive therapies in ET is suggested but not proven.

    • Impact:

    • LT is a serious, largely unpredictable complication of ET.
    • Current data on myelosuppressive treatment risks in ET are inconclusive.
    • Further large-scale prospective studies are needed to clarify treatment risks.
    • Cytotoxic therapy in ET should be reserved for specific patient groups until risks are better understood.